FAM162A

Across TCGA pan-cancer cohorts, FAM162A mass-spec protein differs between tumor and matched normal tissue in 7 of 18 cancer types tested, making tumor–normal expression one of FAM162A’s most consistent transcriptional readouts.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where FAM162A mass-spec protein is repressed in tumor relative to normal tissue. In most cancer types FAM162A is over-expressed in tumor, although a few such as HNSC and COAD show the opposite, repressed pattern.

HNSC, COAD, and LSCC are the cancer types where FAM162A tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in FAM162A mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
HNSC	All	IV	−0.682	<.001	11	view →
COAD	Female	III,IV	−0.677	<.001	11	view →
LSCC	Male	All	+1.194	<.001	9	view →
LUAD	Female	III,IV	+0.745	<.001	9	view →
PDAC	Female	All	−1.119	<.001	6	view →
CCRCC	All	All	−0.242	<.001	4	view →
OV	All	All	+0.496	.008	2	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 7 strongest of 7 lineages.

FAM162A–HNSC

Open the HNSC breakdown →